President Donald Trump signed a new Executive Order on 2 April 2026 that threatens up to 100% tariffs on patented pharmaceuticals from firms that do not negotiate pricing or on‑shoring agreements with the United States. Key Developments Companies with a most‑favoured‑nation (MFN) pricing deal and active U.S. production will face 0% tariff . Firms building U.S. facilities but lacking an MFN deal incur a 20% tariff , rising to 100% after four years . Negotiation windows: 120 days for large firms, 180 days for smaller ones, before the 100% rate becomes effective. The administration has already secured 17 pricing deals , with 13 signed. Separate trade frameworks set tariffs for certain countries: EU, Japan, Korea, Switzerland at 15% ; the U.K. at 10% , slated to fall to 0% under future agreements. Parallel update to the Section 232 -based duties on steel, aluminium and copper, shifting calculation to full customs value. Important Facts The order cites “the threatened impairment of national security posed by imports of pharmaceuticals and pharmaceutical ingredients” as justification. It follows the first anniversary of Trump’s “Liberation Day” tariffs, many of which were struck down by the Supreme Court in February 2026. The President continues to rely on International Emergency Economic Powers Act (IEEPA) for broader import controls, though that specific authority was recently invalidated. Industry reaction is cautious. Stephen J. Ubl, CEO of the pharma trade group PhRMA, warned that steep duties on “cutting‑edge medicines” could raise costs and jeopardise billions of dollars in U.S. investment, despite the country’s already sizable biopharma manufacturing base. UPSC Relevance Understanding this development touches on several GS papers: GS 3 – Economy: The use of tariff as a tool to address the trade deficit and to promote domestic manufacturing. GS 2 – Polity: The legal basis of the order— Section 232 and the now‑struck‑down IEEPA —illustrates executive powers in trade policy. GS 4 – Ethics & Integrity: The order raises questions about the balance between national security, public health, and the ethical implications of using trade barriers to extract concessions from private firms. Way Forward Students should monitor how the negotiation windows unfold and which companies secure MFN deals. Potential outcomes include: Reduced drug prices for U.S. consumers if major firms accept the terms. Retaliatory measures from affected trading partners, possibly affecting broader U.S. export sectors. Legal challenges invoking the Supreme Court’s recent stance on executive overreach in trade. For the UPSC, the episode offers a live case study of trade policy instruments, executive authority, and their macro‑economic and geopolitical ramifications.